57 related articles for article (PubMed ID: 38743346)
41. Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer.
Dolhain J; Janssens W; Mesaros N; Hanssens L; Fierens F
Expert Rev Vaccines; 2018 Jun; 17(6):513-524. PubMed ID: 29920121
[TBL] [Abstract][Full Text] [Related]
42. PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives.
Gevaert T; Cimadamore A; Montironi R; Eckstein M
Curr Drug Targets; 2021; 22(2):162-170. PubMed ID: 32386490
[TBL] [Abstract][Full Text] [Related]
43. Positron emission tomography imaging of meningioma in clinical practice: review of literature and future directions.
Cornelius JF; Langen KJ; Stoffels G; Hänggi D; Sabel M; Jakob Steiger H
Neurosurgery; 2012 Apr; 70(4):1033-41; discussion 1042. PubMed ID: 22426047
[TBL] [Abstract][Full Text] [Related]
44. Lymphoplasmacyte rich meningioma. A case report and review of the literature.
Bruno MC; Ginguené C; Santangelo M; Panagiotopoulos K; Piscopo GA; Tortora F; Elefante A; De Caro ML; Cerillo A
J Neurosurg Sci; 2004 Sep; 48(3):117-24; discussion 124. PubMed ID: 15557881
[TBL] [Abstract][Full Text] [Related]
45. Clinical significance of checkpoint regulator "Programmed death ligand-1 (PD-L1)" expression in meningioma: review of the current status.
Karimi S; Mansouri S; Nassiri F; Bunda S; Singh O; Brastianos PK; Dunn IF; Zadeh G
J Neurooncol; 2021 Feb; 151(3):443-449. PubMed ID: 33611710
[TBL] [Abstract][Full Text] [Related]
46. Molecular alterations in meningioma: prognostic and therapeutic perspectives.
Birzu C; Peyre M; Sahm F
Curr Opin Oncol; 2020 Nov; 32(6):613-622. PubMed ID: 32890025
[TBL] [Abstract][Full Text] [Related]
47. Controversies in the role of preoperative embolization in meningioma management.
Singla A; Deshaies EM; Melnyk V; Toshkezi G; Swarnkar A; Choi H; Chin LS
Neurosurg Focus; 2013 Dec; 35(6):E17. PubMed ID: 24289125
[TBL] [Abstract][Full Text] [Related]
48. Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs.
Dasanu CA; Alvarez-Argote J; Limonadi FM; Codreanu I
Expert Opin Biol Ther; 2019 Feb; 19(2):99-104. PubMed ID: 30556741
[TBL] [Abstract][Full Text] [Related]
49. Neurocognitive considerations in the treatment of meningioma with radiation therapy: applications for quantitative neuroimaging and precision radiation medicine.
Hopper A; Salans M; Karunamuni R; Hattangadi-Gluth JA
J Neurooncol; 2023 Jan; 161(2):277-286. PubMed ID: 36572802
[TBL] [Abstract][Full Text] [Related]
50. Noncoding RNA landscape and their emerging roles as biomarkers and therapeutic targets in meningioma.
Joshi R; Sharma A; Kulshreshtha R
Mol Ther Oncol; 2024 Mar; 32(1):200782. PubMed ID: 38596289
[TBL] [Abstract][Full Text] [Related]
51. Clinical potential of meningioma genomic insights: a practical review for neurosurgeons.
Karsy M; Azab MA; Abou-Al-Shaar H; Guan J; Eli I; Jensen RL; Ormond DR
Neurosurg Focus; 2018 Jun; 44(6):E10. PubMed ID: 29852774
[TBL] [Abstract][Full Text] [Related]
52. Radiation-associated meningiomas in children: clinical, pathological, and cytogenetic characteristics with a critical review of the literature.
Elbabaa SK; Gokden M; Crawford JR; Kesari S; Saad AG
J Neurosurg Pediatr; 2012 Oct; 10(4):281-90. PubMed ID: 22900483
[TBL] [Abstract][Full Text] [Related]
53. Implications and interchangeability of meningioma biomarkers for clinical trials and clinical practice.
Raleigh DR; Chen WC; Gondi V; Rogers L; Mehta M
J Neurooncol; 2024 May; ():. PubMed ID: 38743346
[No Abstract] [Full Text] [Related]
54. Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications.
Dowlat HA; Kuhlmann MK; Khatami H; Ampudia-Blasco FJ
Diabetes Obes Metab; 2016 Aug; 18(8):737-46. PubMed ID: 27097592
[TBL] [Abstract][Full Text] [Related]
55. Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group.
Huang RY; Bi WL; Weller M; Kaley T; Blakeley J; Dunn I; Galanis E; Preusser M; McDermott M; Rogers L; Raizer J; Schiff D; Soffietti R; Tonn JC; Vogelbaum M; Weber D; Reardon DA; Wen PY
Neuro Oncol; 2019 Jan; 21(1):26-36. PubMed ID: 30137421
[TBL] [Abstract][Full Text] [Related]
56. The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable.
Afzali A; Furtner D; Melsheimer R; Molloy PJ
Adv Ther; 2021 May; 38(5):2077-2093. PubMed ID: 33745111
[TBL] [Abstract][Full Text] [Related]
57. Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?
Alvarez DF; Wolbink G; Cronenberger C; Orazem J; Kay J
BioDrugs; 2020 Dec; 34(6):723-732. PubMed ID: 32990892
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
